Target Enzymes Considered for the Treatment of Alzheimer’s Disease and Parkinson’s Disease

Abstract EN

Various amyloidogenic proteins have been suggested to be involved in the onset and progression of neurodegenerative diseases (ND) such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Particularly, the aggregation of misfolded amyloid-β and hyperphosphorylated tau and α-synuclein are linked to the pathogenesis of AD and PD, respectively.

In order to care the diseases, multiple small molecules have been developed to regulate the aggregation pathways of these amyloid proteins.

In addition to controlling the aggregation of amyloidogenic proteins, maintaining the levels of the proteins in the brain by amyloid degrading enzymes (ADE; neprilysin (NEP), insulin-degrading enzyme (IDE), asparagine endopeptidase (AEP), and ADAM10) is also essential to cure AD and PD.

Therefore, numerous biological molecules and chemical agents have been investigated as either inducer or inhibitor against the levels and activities of ADE.

Although the side effect of enhancing the activity of ADE could occur, the removal of amyloidogenic proteins could result in a relatively good strategy to treat AD and PD.

Furthermore, since the causes of ND are diverse, various multifunctional (multitarget) chemical agents have been designed to control the actions of multiple risk factors of ND, including amyloidogenic proteins, metal ions, and reactive oxygen species.

Many of them, however, were invented without considerations of regulating ADE levels and actions.

Incorporation of previously created molecules with the chemical agents handling ADE could be a promising way to treat AD and PD.

This review introduces the ADE and molecules capable of modulating the activity and expression of ADE.